Invited talks and seminars

2020

[11] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” 2020 International Conference of Korean Society of Pharmaceutical Sciences and Technology, Nov 19-20, 2020, Seoul, South Korea.

[10] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” Pharmaceutical Seminar, College of Pharmacy, Chungbuk National University, Nov 5, 2020, Cheongju, South Korea.

[9] Yonghyun Lee “Nano-biomedicine platform for anti-cancer and anti-inflammation therapy” Outcome Research Workshops, College of Pharmacy, Ewha Womans Univerisity, Aug 18, 2020, Seoul, South Korea.

[8] Yonghyun Lee “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” Pharmaceutical Seminar, College of Pharmacy, Ewha Womans Univerisity, Apr 02, 2020, Seoul, South Korea.

2012-2019

[7] Yonghyun Lee and James J. Moon. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” 2019 Biomedical Engineering Society Annual Meeting (BMES), Oct 16-19, 2019, Philadelphia, USA.

[6] Yonghyun Lee and James J. Moon. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” The 46th Annual Meeting & Exposition of the Controlled Release Society (CRS), Jul 21-24, 2019, Valencia, Spain.

[5] Yonghyun Lee and James Moon. “Hyaluronic acid-bilirubin nanoparticles for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” Cancer Hematopoiesis and Immunology Program (CHI Seminar), Rogel Cancer Center, University of Michigan, Mar 1, 2019, Ann Arbor, U.S.A.

[4] Yonghyun Lee and James Moon. “Hyaluronic acid-bilirubin nanoparticles for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis” Pharmaceutical Sciences Seminar, College of Pharmacy, University of Michigan, Dec 5, 2018, Ann Arbor, U.S.A.

[3] Yonghyun Lee. “Development of new drug candidates using novel approaches” The 1st KAST-KSSEA Young Generation Scientist and Engineers Open Forum. Dec 7-12, 2016, Stockholm, Sweden.

[2] Yonghyun Lee and Sangyong Jon. “Development of a Histone H1-Specific Aptide as a Novel Apoptotic Imaging Probe and Evaluation for Monitoring Anti-Cancer Drug Responses” 2014 The Korean Society of Molecular Imaging. May 10, 2014, Daegu, South Korea.

[1] Yonghyun Lee and Yunjin Jun. “Synthesis and evaluation of N-succinylaspart-1-yl celecoxib as a colon specific prodrug of celecoxib.” Symposium on Development and research of original new drug, July 4-6, 2012, Shenyang, China.